Company Overview
Company Type: Public Company
Website: www.imv-inc.com
Number of Employees: 63
Ticker: IMVI.Q (OTCPK)
Year Founded: 2000


Business Description
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company’s lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
0.2
EBITDA
(54.4)
Total Enterprise Value
10.7
TEV/EBITDA
NM
EBIT
(55.3)
Cash & ST Invst.
29.2
P/Diluted EPS Before Extra
NM
Net Income
(52.2)
Total Debt
39.7
Price/Tang BV
NM
Capital Expenditure
(1.5)
Total Assets
43.1
Total Debt/EBITDA
NM




Currency in CAD in mm, LTM as of Dec-31-2022 TEV and Market Cap are calculated using a close price as of Oct-04-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)




Non-Periodic Estimates

Recommendation
Outperform (2.00)
Target Price
8.14
Potential Upside
53,262.19%


Key Professionals
Name
Title
Hall, Andrew 
CEO & Director
Davison, Brittany 
Chief Accounting Officer, Corporate Secretary & Director
Graff, Jeremy R.
Chief Scientific Officer
Davan, Delphine 
Senior Director of Communications & Investor Relations
Fiset, Stephan 
Vice President of Clinical Research

Key Board Members
Name
Title
Bailey, Michael P.
Independent Chairman
Hall, Andrew 
CEO & Director
Davison, Brittany 
Chief Accounting Officer, Corporate Secretary & Director
Kuvalanka, Kyle D.
Independent Director
Bhardwaj, Nina 
Member of Scientific & Clinical Advisory Committee
Iglesias, Jose L.
Member of Scientific & Clinical Advisory Committee
Kalos, Michael 
Independent Director and Member of Scientific & Clinical Advisory Committee
Kazmi, Shabnam 
Independent Director
Maleki, Saman 
Independent Director
Warmuth, Markus 
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
130 Eileen Stubbs Avenue Suite 19 | Dartmouth, NS | B3B 2C4 | Canada
Phone: 902 492 1819   Fax: 902 492 0888

Current and Pending Investors
Altium Capital Management LP, Brigus Capital Inc., Cato BioVentures, CTI Life Sciences, Fonds de solidarité FTQ, Horizon Technology Finance Management, LLC, Invest Nova Scotia, Lumira Ventures, Ruffer LLP, VR Adviser, LLC

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.02
Market Cap (mm)
0.2
Open
 0.02
Shares Out. (mm)
11.7
Previous Close
 0.02
Float %
94.3%
Change on Day
0.00
Shares Sold Short (mm)
0.2
Change % on Day
(2.6)%
Dividend Yield %
-
Day High/Low
 0.04/ 0.0089
Diluted EPS Excl. Extra Items
(6.26)
52 wk High/Low
 7.20/ 0.0003
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0026
Avg 3M Dly Vlm (mm)
0.02
Beta 5Y
1.20


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Rhino Resources Inc.
As of September 30, 2009, Rhino Resources Inc. was acquired by ImmunoVaccine Technologies, Inc., in a reverse merger transaction. Rhino Resources, Inc. operates as a blank check company. The company was incorporated in 2007 and is based in Halifax, Canada.

United States and Canada
Asset Management and Custody Banks
-
0.00
0.00
Immunotope, Inc.
Immunotope, Inc., a clinical stage biotechnology company, develops immunotherapy products for the treatment and prevention of cancer and chronic viral infections. It offers IMT-1012 immunotherapeutic vaccine, a multivalent cancer therapeutic mixture of various novel antigens; therapeutic vaccines that are intended for the treatment of ovarian, breast, prostate, lung, pancreatic, and colon cancers; and vaccines for HBV, HCV, HIV, influenza, and dengue virus infections. The company also focuses on developing autoantibody-based biomarkers for early-stage detection of cancer. In addition, it offers immuno proteomics services for antigen discovery and characterization; analysis of major histocompatibility complex processing of proteins in genetic constructs; and analysis of antigen specificity post cell-based immunotherapies. The company was incorporated in 2002 and is based in Doylestown, Pennsylvania. Immunotope, Inc. operates as a subsidiary of IMV Inc.

United States and Canada
Biotechnology
-
-
-
ImmunoVaccine Technologies Inc

United States and Canada
-
-
-
-
IMV USA INC
IMV USA INC operates as a subsidiary of IMV Inc.

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Dec-21-2022
-
Shelf Registration
Target
IMV Inc. (OTCPK:IMVI.Q)


0.29
Dec-19-2022
-
Public Offering
Target
IMV Inc. (OTCPK:IMVI.Q)


9.00
Dec-16-2022
Dec-20-2022
Public Offering
Target
IMV Inc. (OTCPK:IMVI.Q)


9.00
Aug-4-2022
-
Public Offering
Target
IMV Inc. (OTCPK:IMVI.Q)


50.00
Jul-11-2022
-
Shelf Registration
Target
IMV Inc. (OTCPK:IMVI.Q)


200.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-22-2023
Delistings
IMV Inc. Files Form 15
Sep-22-2023
Shelf Registration Filings
IMV Inc. has closed its Shelf Registration dated June 01, 2018 in the amount of $36.132813 million.
Sep-22-2023
Shelf Registration Filings
IMV Inc. has closed its Shelf Registration dated May 27, 2020 in the amount of $3.847875 million.
Sep-22-2023
Shelf Registration Filings
IMV Inc. has closed its Shelf Registration dated June 30, 2020 in the amount of $1.555 million.
Sep-22-2023
Shelf Registration Filings
IMV Inc. has withdrawn its Shelf Registration dated March 25, 2022 in the amount of $1.724328 million.

Competitors
Emergent BioSolutions Inc. (NYSE:EBS)

M&A Advisors
McInnes Cooper LLP


Advisors
Most Recent Auditor
PricewaterhouseCoopers LLP
M&A Advisors
McInnes Cooper LLP
Private Placement Advisors
Beacon Securities Limited, Echelon Wealth Partners Inc., Macquarie Private Wealth Inc., McCarthy Tétrault LLP, Research Capital Corporation, SP Angel Corporate Finance LLP, Troutman Pepper Hamilton Sanders LLP
Public Offering Advisors
H.C. Wainwright & Co., LLC, McCarthy Tétrault LLP, PricewaterhouseCoopers LLP, PricewaterhouseCoopers LLP, Canada, Troutman Pepper Hamilton Sanders LLP


Most Recent Auditor
PricewaterhouseCoopers LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

03:47 AM
IMVI.Q
IMV Inc 2023_10_05
Reports
14
ValuEngine, Inc.

Oct 02, 2023 04:42 AM
IMVI.Q
ValuEngine Rating and Forecast Report for IMVIQ
Reports
11
GlobalData

Sep 14, 2023 11:56 PM
IMVI.Q
IMV Inc (IMV.TSE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
143
GlobalData

Sep 12, 2023 03:49 AM
IMVI.Q
IMV Inc (IMV.TSE) - Financial Analysis Review
Reports
490
S&P Global Compustat

Sep 07, 2023 03:37 AM
IMVI.Q
IMV Inc 2023_09_07
Reports
14
GlobalData

Aug 25, 2023 03:19 AM
IMVI.Q
IMV Inc (IMVIQ.OTC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
60
H.C. Wainwright & Co.
Pantginis, Joseph
Aug 08, 2023 04:01 AM
IMVI.Q
IMV: Dropping Coverage
Reports
6
S&P Global Compustat

Jul 06, 2023 03:15 AM
IMVI.Q
IMV Inc 2023_07_06
Reports
14
MarketLine

Jun 26, 2023 06:01 AM
IMVI.Q
Immunovaccine Inc
Reports
34
GlobalData

Jun 12, 2023 06:30 AM
IMVI.Q
IMV Inc (IMV.TSE) - Financial Analysis Review
Reports
490


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Fonds de solidarité FTQ

654,010

5.58

0.0

Dec-31-2022


Hall CA, James W.

6,100

0.05

0.0

Mar-20-2023


Geode Capital Management, LLC

4,875

0.04

0.0

Aug-31-2023


CATAM Asset Management AG

2,000

0.02

0.0

Jun-30-2023


Davison C.A., CPA, Brittany 

1,520

0.01

0.0

Mar-20-2023


Maleki Ph.D., Saman 

516

0.00

0.0

Mar-31-2023


Rhumbline Advisers Ltd Partnership

51

0.00

0.0

Jun-30-2023


Millennium Management LLC

0

0.00

0.0

Jun-30-2023


Larson Financial Group, LLC

0

0.00

0.0

Jun-30-2023


Two Sigma Investments, LP

0

0.00

0.0

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Rhumbline Advisers Ltd Partnership
51
51

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Ruffer LLP
0
(321,952)
Susquehanna International Group, LLP, Asset Management Arm
0
(63,537)
National Bank Investments Inc.
0
(53,857)
LexAurum Advisors, LLC
0
(51,095)
Wells Fargo & Company, Securities and Brokerage Investments
0
(46,175)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
Date/Time
Headline
Source
Sep-12
EKF Diagnostics hires CFO from Trellus Health, latter names successor
Alliance News


Company Coverage
This company is not on any Coverage List.

Products
AVALON (Future), BioThrax, DeCidE1 (Future), DepoVax (Future), DPX-0907 (Future), DPX-BRAF (Future), DPX-COVID-19 (Future), DPX-E7 (Future), DPX-NEO (Future), DPX-RSV, DPX-SurMAGE (Future), DPX-Survivac + mCPA + ID01 (Future), DPX-Survivac + mCPA + PD-1 (Future), DPXE7 + mPCA (Future), IRX-2 (Future), maveropepimut-S (Future), VITALIZE (Future)


Upcoming Events
Date/Time
Type
Dec-14-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Reporting Owner(s)
Source
Form Type
Size
Sep-22-2023
-
IMV Inc. (OTCPK:IMVI.Q)

SEC
F-10POS
32 KB
Sep-22-2023
-
IMV Inc. (OTCPK:IMVI.Q)

SEC
F-10POS
31 KB
Sep-22-2023
-
IMV Inc. (OTCPK:IMVI.Q)

SEC
F-10POS
30 KB
Jul-26-2023
-
IMV Inc. (OTCPK:IMVI.Q)

SEDAR
News Releases
184 KB
Jul-26-2023
Jul-26-2023
IMV Inc. (OTCPK:IMVI.Q)

SEC
6-K
44 KB
Jul-10-2023
-
IMV Inc. (OTCPK:IMVI.Q)
The NASDAQ Stock Market LLC
SEC
25-NSE
4 KB
May-08-2023
-
IMV Inc. (OTCPK:IMVI.Q)

SEDAR
News Releases
475 KB
May-08-2023
May-08-2023
IMV Inc. (OTCPK:IMVI.Q)

SEC
6-K
36 KB
Mar-31-2023
-
IMV Inc. (OTCPK:IMVI.Q)

SEDAR
News Releases
155 KB
Mar-31-2023
Mar-31-2023
IMV Inc. (OTCPK:IMVI.Q)

SEC
6-K
34 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Hall CA, James W. (Former Independent Director)
Aug-30-2021
Common Shares
6,100
108,787
Open Market Acquisition
New
Multiple
Labbe C.A., C.P.A., CA, CPA, ICD, Pierre  (Former Chief Financial Officer)
Jul-23-2021
Common Shares
2,000
40,401
Open Market Acquisition
13.28
Multiple
Ors B.Sc., M.A., M.B.A., Frederic  (Former CEO & Director)
Jul-23-2021
Common Shares
10,000
202,004
Open Market Acquisition
33.17
Multiple
Fonds de solidarité FTQ
Jul-20-2021
Common Shares
142,857
3,434,374
Open Market Acquisition
27.95
Multiple
Ors B.Sc., M.A., M.B.A., Frederic  (Former CEO & Director)
Jan-21-2021
Common Shares
5,155
132,876
Derivative Exercise and Retained Stock
20.63
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Bailey, Michael P.
Independent Chairman
902 492 1819
902 492 0888
mbailey@aveooncology.com
Hall, Andrew 
CEO & Director
902 492 1819
902 492 0888

Davison, Brittany 
Chief Accounting Officer, Corporate Secretary & Director
902 492 1819
902 492 0888

Kuvalanka, Kyle D.
Independent Director
902 492 1819
902 492 0888

Bhardwaj, Nina 
Member of Scientific & Clinical Advisory Committee
902 492 1819
902 492 0888

Iglesias, Jose L.
Member of Scientific & Clinical Advisory Committee
902 492 1819
902 492 0888

Kalos, Michael 
Independent Director and Member of Scientific & Clinical Advisory Committee
902 492 1819
902 492 0888

Kazmi, Shabnam 
Independent Director
902 492 1819
902 492 0888

Maleki, Saman 
Independent Director
902 492 1819
902 492 0888

Warmuth, Markus 
Independent Director
902 492 1819
902 492 0888
mwarmuth@monterosatx.com
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Hall, Andrew 
CEO & Director
902 492 1819
902 492 0888

Davison, Brittany 
Chief Accounting Officer, Corporate Secretary & Director
902 492 1819
902 492 0888

Graff, Jeremy R.
Chief Scientific Officer
902 492 1819
902 492 0888

Davan, Delphine 
Senior Director of Communications & Investor Relations
(902) 492.1819x1049
902 492 0888
ddavan@imv-inc.com
Fiset, Stephan 
Vice President of Clinical Research
902 492 1819
902 492 0888

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
